Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD). Macroplastique has been used in Europe since 1991 and has proven to be an effective and safe treatment alternative for those suffering from SUI.
-Unique delivery system ensures precise implantation
-May be performed in the office
-Permanent implants: non-degradable, non-resorbable
-Soft, flexible, textured implant particles create an excellent matrix for collagen deposition
-Histological examination of tissue explants revealed no evidence of particle migration
Macroplastique demonstrated excellent clinical efficacy 122 patients received Macroplastique and were followed for 12 months from initial treatment 75 of 122 (61.5%) were improved at 12 months based on Stamey grade 45 of 122 (36.8%) were dry based on Stamey grade No serious treatment-related adverse events were associated with Macroplastique procedures Twenty-four month follow-up data were available on 84 Macroplastique subjects. Of these 84 subjects, 63 had improvement in Stamey Grade at 24 months, 28 of whom were dry.
63 Canterbury Road., Brooklyn, CT 06234